Trial Profile
A Post-market Registry of the BioMatrix Alpha TM (Cobalt Chromium Biolimus A9TM (BA9TM) Drug-eluting Stent)
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors Biosensors International Group
- 24 Aug 2016 New trial record